Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Abdominal Surgery
Conditions: Pain, Postoperative Interventions: Drug: LPM3480392 Injection; Drug: Placebo; Drug: morphine hydrochloride injection Sponsors: Luye Pharma Group Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
Comparative Bioavailability of Intranasal Epinephrine
Conditions: Anaphylaxis; Anaphylactic Reaction Interventions: Drug: A: Epinephrine injection; Drug: B: FMXIN002 3.6mg; Drug: C: FMXIN002 4.0mg Sponsors: Nasus Pharma; Hadassah Medical Organization; Medistat Ltd., Israel; Pharma Medica Research, Inc. Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer
Conditions: Pancreatic Cancer Interventions: Drug: NP137 Sponsors: Nabeel Badri; NETRIS Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
Bayer ’s AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure (CHF)
Berlin, Germany/Research Triangle Park, North Carolina, USA, January 11, 2024– Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, have announced... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 11, 2024 Category: Pharmaceuticals Source Type: clinical trials
Reduced Blood Lead Levels Linked to Lower Blood Pressure in American Indians
Reductions correlated with long-term cardiovascular health improvements in NIH-funded study.
January 11, 2024 -- Researchers have linked a decade-long decline in the blood lead levels of American Indian adults to long-term cardiovascular health... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 11, 2024 Category: Pharmaceuticals Source Type: clinical trials
A Multicenter, Randomized, Double-blind, Three-arm, Parallel Clinical Endpoint Bioequivalence Study of Monometasone Furoate Nasal Spray in Patients With Seasonal Allergic Rhinitis
Conditions: Seasonal Allergic Rhinitis Interventions: Drug: Mometasone furoate as a nasal spray Sponsors: Zheng Liu ENT; Zhejiang Xianju Pharma Tech. Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2024 Category: Research Source Type: clinical trials
Open Enrollment Commences for Phase 1b/2 Study Evaluating Ampligen in Combination with Imfinzi for the Treatment of Pancreatic Cancer
OCALA, Fla., Jan. 10, 2024. AIM ImmunoTech Inc. (“AIM” or the“Company”) today announced that enrollment is open at Erasmus Medical Center (“Erasmus MC”) in a Phase 1b/2 clinical trial combining AIM’s... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 10, 2024 Category: Pharmaceuticals Source Type: clinical trials
Reduced Drug Use is a Meaningful Treatment Outcome for People with Stimulant Use Disorders
January 10, 2024 -- Reducing stimulant use was associated with significant improvement in measures of health and recovery among people with stimulant use disorder, even if they did not achieve total abstinence. This finding is according to an... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 10, 2024 Category: Pharmaceuticals Source Type: clinical trials
Marius Pharmaceuticals Announces Pilot Study Exploring the Effect of Its Oral Testosterone Therapy, KYZATREX on Male Fertility
RALEIGH, N.C., Jan. 9, 2024. Marius Pharmaceuticals a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announced it has initiated a pilot study to better understand the effect of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 9, 2024 Category: Pharmaceuticals Source Type: clinical trials
A Common Marker of Neurological Diseases May Play Role in Healthy Brains
January 9, 2024 -- Researchers have discovered that a protein called phosphorylatedα-synuclein, which is associated with several neurodegenerative diseases such as Parkinson’s disease and Lewy body dementia, is also involved in the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 9, 2024 Category: Pharmaceuticals Source Type: clinical trials
An Exploratory Study of MT-2990 in Patients With AAV
Conditions: Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV) Interventions: Drug: MT-2990 Sponsors: Mitsubishi Tanabe Pharma Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2024 Category: Research Source Type: clinical trials
Bayer Starts Phase II Study NIRVANA to Evaluate Elinzanetant in Women with Sleep Disturbances Associated with Menopause
Berlin, January 8, 2024– Bayer, a global leader in women’s healthcare, announced today the expansion of the clinical development program for the investigational compound elinzanetant. The first study participants were recently enrolled... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 8, 2024 Category: Pharmaceuticals Source Type: clinical trials
Bayer ’s Elinzanetant Meets All Primary and Key Secondary Endpoints in Pivotal OASIS 1 and 2 Phase III Studies
Berlin, January 8, 2024– Bayer today announced positive top-line results of the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo. Elinzanetant successfully... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 8, 2024 Category: Pharmaceuticals Source Type: clinical trials
Residential Addiction Treatment for Adolescents is Scarce and Expensive
January 8, 2024 -- Access to residential addiction treatment centers caring for U.S. adolescents under 18 years old in the United States is limited and costly, according to a new study supported by the National Institutes of Health. Researchers... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 8, 2024 Category: Pharmaceuticals Source Type: clinical trials
Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
NORTH CHICAGO, Ill., Jan. 8, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced Phase 2 results showing adults with moderate to severe hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 8, 2024 Category: Pharmaceuticals Source Type: clinical trials
